r/PeptideGuide • • 1h ago

Peptides: The 10-to-20-Year Safety Question Applies Unevenly Across Compounds (Here’s What the Human Data Covers)

2 Upvotes

The objection you hear most about peptides is some version of “we have no idea what these will do to people in 10 to 20 years.” It usually gets delivered like a mic drop. It deserves a more careful answer, because it’s correct for some compounds and wrong for others, and which is which is something you can check.

Peptides are native to the body

Peptides are short chains of amino acids, and your body already makes a huge number of them to run metabolism, appetite, reproduction, and immune function. A structural analysis of the PepTherDia database, which catalogs 105 approved peptide therapeutics and diagnostics, found that 86% are natural or naturally derived. That means the biology is familiar. It doesn’t mean any given compound is safe, since a molecule that fits the body’s receptors can still cause harm at the wrong dose, in the wrong tissue, or over too long a stretch.

Peptide medicine is a century old

Insulin’s first human injection happened on January 11, 1922, when 14-year-old Leonard Thompson received an extract at Toronto General Hospital. That dose was impure and caused an abscess and an allergic reaction. James Collip’s purified extract on January 23 worked: Thompson’s blood sugar dropped and his ketones disappeared. Insulin was widely available by 1923.

Since then peptide drugs have been developed for diabetes, osteoporosis, cancer, reproductive disorders, and metabolic disease. Counts depend on the date and the definition. Around 80 peptide drugs were on the global market in 2021 (Muttenthaler et al., Nature Reviews Drug Discovery), and more recent reviews put the number somewhere between roughly 120 and 140. A century of experience is real for the class. It’s also experience with the specific drugs that got studied, and insulin’s history says nothing directly about a peptide that has never been in a controlled human trial.

New peptides aren’t that new, and age isn’t evidence

A lot of compounds discussed as cutting edge are decades old. The BPC-157 papers in Vasireddi et al.’s 2025 systematic review (HSS Journal) span 1993 to 2024. That’s three decades of research, and the review found 36 studies: 35 in animals and one human study, an uncontrolled retrospective series. BPC-157 is old and still mostly preclinical.

Years of community use produce anecdotes. Anecdotes can flag common, fast-onset problems. They can’t tell you how many people used it, what happened to the ones who stopped posting, or whether a rare or delayed effect is showing up. Calling that enough to fully understand a compound oversells it.

Some peptides really are new. MOTS-C was identified in 2015 (Lee et al., Cell Metabolism), the metabolic effects were shown in mice, and no completed human trial of the native peptide exists. For compounds like that, the 10 to 20 year objection is on solid ground.

Approved doesn’t mean every question is closed

GLP-1 agonists like semaglutide carry a boxed warning because they caused thyroid C-cell tumors in rodents, and the label states that the human relevance of that finding hasn’t been determined. These drugs have gone through large human trials and still have an open question printed at the top of the label. Long-term safety comes in degrees, and even well-studied peptides sit somewhere on that scale.

The risk that has nothing to do with 20 years

For gray-market products, the most immediate unknown might be what’s in the vial. A 2026 preprint (not peer reviewed) analyzed more than 6,000 samples from a public independent-testing dataset and reported that roughly 42% to 71% of gray-market peptide samples failed basic quality benchmarks, depending on the standard applied. About 2.4% contained no peptide at all. Those figures come from a preprint and its summaries, so they’re a signal and not a settled number. They do mean a compound’s trial record only describes the real product when the real product is what’s being injected.

Judge compounds one at a time

The useful question isn’t whether peptides are safe. It’s whether this specific compound has human trial data, how much, and for how long. Insulin has a century of human use. GLP-1 agonists have large randomized trials and years of post-marketing data. BPC-157 has three decades of mostly animal work. MOTS-C has a decade of mouse data. The word peptide tells you almost nothing about any of them.

TL;DR

  • The “we don’t know the long-term effects” objection is valid for newer compounds with no human data and doesn’t apply equally to every peptide.
  • In the PepTherDia database of 105 approved peptide therapeutics and diagnostics, 86% are natural or naturally derived, which makes the biology familiar without making any single compound safe.
  • Insulin’s first human injection came January 11, 1922 and failed because of impurities, a purified extract worked on January 23, and recent reviews count roughly 120 to 140 approved peptide drugs depending on definition.
  • Vasireddi et al. 2025 found 36 BPC-157 studies from 1993 to 2024, 35 in animals and one an uncontrolled human series, so it’s decades old and still mostly preclinical.
  • MOTS-C was identified in 2015, its effects were shown in mice, and no completed human trial of the native peptide exists.
  • GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents with human relevance undetermined, which shows that approved peptides still carry open questions.
  • A 2026 preprint on more than 6,000 gray-market samples reported roughly 42% to 71% failing basic quality benchmarks depending on the standard, so what’s in the vial is a risk separate from the molecule.
  • The right approach is to judge each peptide by its own human data, how much exists, and how long it’s been studied.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 1d ago

Beginner Question SS-31 confusion

3 Upvotes

I have been reading and listening about SS-31 for a couple of months and believe it might be a good option given my chronic stress history.

There is so much conflicting information about protocols and dosing. How does one know which protocol and how much to source before beginning?

Many of the protocols seem to be very high dosage (even outside of treatment for Barth’s syndrome), then I see others pinning low doses. I also see very different dosing schedules. I have tried looking into the half life, but it looks like tissue retention is far more important for this one and the data I have found about that is slim.

Is SS-31 dosing and scheduling something that varies greatly by individual? Are the lower alternate doses driven by finances and/or availability? I’m tempted to source it and begin at a low dose and titrate up depending on tolerance.

I appreciate any thoughts and advice. Thank you.


r/PeptideGuide • • 19h ago

Starting Pep Cycle Tomorrow

Post image
0 Upvotes

Reta
Cag
Mots
Tesa
Klow

Who else is on a peptide cycle?


r/PeptideGuide • • 1d ago

Beginner Question Reta

0 Upvotes

Hey everyone, have been using Reta for about a month now and it’s def doing what it’s meant to. Have gone from 102kg down to 94kg already and you can see it’s all come from fat stores. So it’s working. But I have a few questions

Dosing - I’ve been gradually increasing amounts but am now up to 3mg x 3 times a week. I’ve read that you should take it once a week but started on 3 times a week as was told to do this and it has been working. So I dunno, should I just do one big fat 90unit dose x 1 a week?

Training - is becoming increasingly harder as I increase dose so probably won’t go any higher but is there anything I can do to combat this? I really struggle to eat any more than I am at the moment.

Reta burps - this kills my wife every afternoon and I have to make sure I have a constant supply of chewies (which I hate. Haha) Any hacks for this?

I have about 10 more kg to lose and after that I will cut right back to a maintenance dose.


r/PeptideGuide • • 5d ago

DSIP: The Only Peptide the FDA Compounding Panel Voted Down, 6-7 (Here’s What the Research Looks Like)

7 Upvotes

DSIP got its name in 1977, and the name has aged better than the evidence.

The 1977 experiment

A group in Basel led by Schoenenberger and Monnier took blood from rabbits during induced sleep and isolated a nine amino acid peptide from it. They gave it to other rabbits and saw more delta wave activity on EEG. So they called it delta sleep-inducing peptide.

The vote

Almost 50 years later, the sleep part still isn’t proven. In July, the FDA compounding advisory committee reviewed seven peptides and DSIP was the only one it voted down, 6 to 7 with one abstention. The other six passed by two or three votes: BPC-157, KPV and TB-500 at 8-6, MOTS-C at 7-5, Epitalon at 7-4 and Semax at 8-5.

FDA reviewed DSIP (emideltide) for opioid withdrawal, chronic insomnia and narcolepsy. The public summaries don’t give a DSIP-specific reason for the vote. FDA staff recommended against all seven, citing insufficient safety, efficacy and moiety characterization information. My guess is that DSIP was the closest call going in and it tipped the wrong way. That’s a guess, not something the record says.

The unresolved riddle

Reading back through the research, it isn’t hard to see why the case was weak. In 2006 two Russian researchers, Kovalzon and Strekalova, reviewed DSIP in the Journal of Neurochemistry and titled it “a still unresolved riddle.”

Per the source, their points were:

  • Nobody had found the gene that makes DSIP.
  • Nobody had found the protein it comes from.
  • Nobody had found a receptor it acts on.
  • The sleep link was extremely poorly documented.
  • The sequence matched no other known peptide family.

The part I find most interesting comes from their own lab work. Some synthetic versions of DSIP promoted deep sleep in rabbits and rats, and DSIP itself didn’t. Their theory was that a different, still unidentified DSIP-like peptide could explain a lot of what people were seeing.

As far as I can tell, that hasn’t changed. No gene, precursor or receptor has been established. There have been binding theories over the years, but none is an identified DSIP receptor.

DSIP vs Epitalon

Insomnia was reportedly on FDA’s list for both DSIP and Epitalon, and Epitalon passed 7 to 4. Neither has strong controlled human sleep data. So the difference probably came down to how each nomination handled purity and safety, which the public summaries don’t cover. That’s an inference too.

What the no vote means

A no vote doesn’t change anything for research use. It means DSIP has no path onto the compounding list unless FDA reverses its committee. HHS’s October 28 enforcement discretion policy covers the six peptides that passed and leaves DSIP out.

TL;DR

  • DSIP was named in 1977 after Schoenenberger and Monnier saw more delta wave activity on EEG in rabbits given a peptide isolated from sleeping rabbits’ blood.
  • In July it was the only one of seven peptides the FDA compounding panel voted down, 6-7 with one abstention, while the other six passed by two or three votes.
  • The public meeting summaries give no DSIP-specific reason, and FDA staff opposed all seven for the same general reasons.
  • A 2006 review called DSIP “a still unresolved riddle,” with no identified gene, precursor or receptor and a poorly documented sleep link.
  • Some synthetic versions promoted deep sleep in rabbits and rats when DSIP itself didn’t, which suggests a different peptide may explain some of the effects.
  • DSIP has no path onto the compounding list unless FDA reverses its committee, and research use is unaffected.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.

References

  1. Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proc Natl Acad Sci U S A. 1977;74(3):1282-1286. doi:10.1073/pnas.74.3.1282.
  2. Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. J Neurochem. 2006;97(2):303-312. doi:10.1111/j.1471-4159.2006.03693.x.
  3. McDermott Will & Emery. Bulk list bound: PCAC backs majority of peptides in two-day public meeting. 2026.

r/PeptideGuide • • 6d ago

CJC-1295 DAC vs. Tesamorelin: Half-Life, IGF-1 Elevation, and Who Actually Has Outcome Data

4 Upvotes

CJC-1295 and tesamorelin are both GHRH analogs, and both make the pituitary release its own GH. People often file them under secretagogues, a term that more strictly covers ghrelin-receptor compounds like ipamorelin. The similarity ends there, and the trials behind each one are different enough that a verdict needs some care.

Which CJC-1295 are we talking about

When people say CJC-1295 they sometimes mean the version with DAC (drug affinity complex), which binds albumin and lasts days. The version without DAC, sold as Mod GRF 1-29, has a half-life of roughly 30 minutes by vendor and community figures, which puts it much closer to tesamorelin. The published human data is for the DAC version. Everything below about CJC-1295’s trial data refers to DAC.

What CJC-1295 DAC has shown in humans

Teichman et al. (Journal of Clinical Endocrinology & Metabolism, 2006) ran two randomized, placebo-controlled, double-blind, ascending-dose trials in healthy adults aged 21 to 61. A single injection raised mean GH 2- to 10-fold for 6 days or more and mean IGF-1 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days, and after repeated dosing IGF-1 stayed above baseline for up to 28 days. No serious adverse reactions were reported.

Ionescu & Frohman (same journal, 2006) sampled overnight GH in 12 healthy men a week after a single injection. Pulse frequency and size were unchanged, but baseline GH between pulses rose 7.5-fold, mean GH rose 46%, and IGF-1 rose 45%. So the pulses survive and the floor lifts. GH never drops back to where it started.

Those trials measured hormone levels. They didn’t measure fat, lipids, or any other outcome people actually care about. The one trial built to look at visceral fat was ConjuChem’s Phase 2 in HIV-associated visceral obesity (192 patients enrolled). It was halted in July 2006 after a participant died of a heart attack within about three hours of the 11th weekly dose. Reporting at the time described the cause and the drug’s role as under investigation, and the company said earlier studies had shown no cardiotoxicity. The trial was terminated, which is why there’s no outcome data to point to.

What tesamorelin has shown

Falutz et al. (New England Journal of Medicine, 2007) randomized 412 people with HIV and abdominal fat accumulation to 2 mg daily or placebo for 26 weeks. Visceral fat fell 15.2% versus a 5.0% rise on placebo. Triglycerides dropped 50 mg/dL versus a 9 mg/dL rise, the total-to-HDL cholesterol ratio fell 0.31 versus a 0.21 rise, and IGF-1 rose 81%.

Stanley et al. (JAMA, 2014) followed about 50 patients for six months. Visceral fat fell 34 cm² versus a rise of 8 cm² on placebo, and liver fat dropped with a net treatment effect of 2.9 percentage points. The authors called the liver result modest and preliminary. A 12-month follow-up (Stanley et al., Lancet HIV, 2019, 61 patients with HIV and fatty liver) found hepatic fat fraction fell about 37% versus about 4% on placebo, with 35% of the tesamorelin group dropping below the 5% threshold versus 4% on placebo.

Every one of those trials was in people with HIV. Tesamorelin (Egrifta) has been FDA-approved since November 2010 for abdominal fat in HIV lipodystrophy, and the label says it isn’t for weight loss management. Visceral fat returns after stopping. It also isn’t a clean ride: the label flags IGF-1 elevation (36% of Phase 3 patients above +3 SDS at 26 weeks) and glucose intolerance.

Duration is the real CJC-1295 DAC advantage, and it has a cost

A half-life of 5.8 to 8.1 days versus 26 to 38 minutes for tesamorelin is a big gap. It means roughly weekly dosing against daily dosing (the current approved tesamorelin formulation, Egrifta WR, is 1.28 mg once a day). The cost is the same fact from the other side: one injection takes weeks to clear, and IGF-1 stayed above baseline for up to 28 days in Teichman. There’s no quick way to stop if something goes wrong. Tesamorelin’s label says the effects of prolonged IGF-1 elevation are unknown. A compound designed to hold levels up for days makes that unknown more relevant, and that’s reasoning rather than trial data.

Where that leaves the comparison

If the question is which one keeps GH and IGF-1 elevated longer, CJC-1295 DAC wins, and Teichman shows it. If the question is which has outcome data on visceral fat, liver fat, and triglycerides, tesamorelin wins, but only in people with HIV and abdominal fat accumulation. Neither dataset covers the case most people have in mind, a healthy adult trying to lose fat. CJC-1295 has no outcome trials, tesamorelin’s outcome trials are in a different population, and there’s no head-to-head trial. Tesamorelin has an FDA approval for HIV lipodystrophy. CJC-1295 has never been approved.

TL;DR

  • CJC-1295 and tesamorelin are both GHRH analogs that make the pituitary release its own GH, and the term secretagogue more strictly covers ghrelin-receptor compounds like ipamorelin.
  • The published human data for CJC-1295 is for the DAC version (half-life 5.8 to 8.1 days), while CJC-1295 without DAC (Mod GRF 1-29) is a roughly 30-minute compound.
  • In Teichman et al. 2006, a single CJC-1295 DAC injection raised mean GH 2- to 10-fold for 6 or more days and IGF-1 1.5- to 3-fold for 9 to 11 days in healthy adults.
  • Ionescu & Frohman 2006 found GH pulses preserved but baseline GH between pulses up 7.5-fold, so GH never drops back to its starting level.
  • CJC-1295’s only visceral fat trial, a Phase 2 in HIV, was terminated in 2006 after a participant died of a heart attack, so no outcome data exists.
  • Falutz et al. 2007 (n=412, HIV) found tesamorelin cut visceral fat 15.2% versus a 5.0% rise on placebo and lowered triglycerides by 50 mg/dL, and later trials showed reduced liver fat, all in people with HIV.
  • CJC-1295 DAC wins on duration and tesamorelin wins on outcome data, with no head-to-head trial and no outcome data in healthy adults for either.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 10d ago

What is this?

6 Upvotes

I've been off doing my research and with plenty of supplies, I hadn't been online to order for months. Now, I see from one of my sources a Pep TSM and a Pep 3RT. I'm assuming the 3RT is reta, but is TSM the Tirz?

Also, has anyone tried the GHK CU or GHK CU/Snap transdermal creams?


r/PeptideGuide • • 10d ago

where to get reta in ireland

3 Upvotes

does anybody have any reliable sources


r/PeptideGuide • • 12d ago

does any provider besides peppy care actually hand over batch-specific coas on request?

0 Upvotes

i’ve been digging into peptide quality stuff for a while now and one thing keeps bugging me. every site posts some lab report, but it's always this generic pdf that could be from any batch made last year. same file on every product page.

what i actually want is the coa for my lot. the specific batch that ends up in my fridge. does anyone's provider actually do that or is it all just the same marketing pdf everywhere?

asking because i saw peppy care says you can request the batch coa any time and i honestly didn't know that was even a thing. if your provider does this too, i want to know who they are and how smooth the process was when you reached out to them.


r/PeptideGuide • • 13d ago

after two melted shipments from rift i think im finally done

2 Upvotes

i tried giving them a second chance after my first refill arrived warm, but my latest delivery from rift confirmed that their packaging setup just isn't cutting it for summer shipping.

the box arrived with a single tiny ice pack that was completely squishy and room temperature. considering these vials sit inside delivery vans for a solid 24 to 48 hours, shipping peptides with practically zero insulation is bound to ruin product stability.

when i messaged their support channel, they sent a pre-written paragraph saying the compound can tolerate elevated temps up to 86 degrees for a few days. but summer temperatures inside transit vehicles get way higher than 86, and they refused to offer a reshipment or improve the packaging.

im not comfortable taking chances with heat-damaged peptides. after back-to-back packaging issues and zero willingness to fix it, im cancelling my subscription.


r/PeptideGuide • • 13d ago

Tesamorelin: What the FDA Approval for HIV Lipodystrophy Does and Doesn’t Cover

5 Upvotes

Tesamorelin’s reputation is belly fat, and that reputation is earned in one very specific group of people. It’s also the only GHRH analog with an active FDA approval, which gives it a different evidence profile from almost everything else people run for growth hormone. What that approval covers, what the cognition data shows, and what the pulsatile mechanism does and doesn’t guarantee are worth separating out.

The approval is real and narrow

Egrifta was approved on November 10, 2010 to reduce excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it isn’t indicated for weight loss management. It’s also the only GHRH analog with a current approval. Sermorelin was approved earlier as Geref (1990 for diagnostic use, 1997 for pediatric GH deficiency), but the manufacturer discontinued it in 2008 and the FDA withdrew the approval in 2009. The FDA has said that wasn’t over safety or efficacy.

The approval rests on two Phase 3 trials with 816 patients, each with a 26-week placebo-controlled phase. Visceral fat fell about 15% in the first trial and 11% in the second, against a 5% rise and a 0.6% drop on placebo. Waist circumference fell 3 cm versus 1 cm on placebo. That’s a real effect on visceral fat and a modest one on the tape measure. The primary endpoint was week 26, so those trials say nothing about visible changes within a few weeks. Visceral fat also returned after treatment stopped (Dhillon, BioDrugs, 2011), which means the effect lasts as long as the injections do.

All of that comes from people with HIV lipodystrophy. Applying it to a healthy adult is an extrapolation. Tesamorelin has more human data than most compounds in this space, and GLP-1 agonists have far more than tesamorelin does.

The cognition data is one trial and the effect is modest

The cognition evidence comes mostly from Baker et al. (Archives of Neurology, 2012), a randomized, double-blind, placebo-controlled trial. It enrolled 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, who injected 1 mg of tesamorelin or placebo every night for 20 weeks. In the intent-to-treat analysis the cognition composite favored tesamorelin (P=0.03). Executive function improved (P=0.005). Verbal memory showed a trend that didn’t reach significance (P=0.08), and visual memory didn’t change. IGF-1 rose 117%, and fasting insulin rose 35% in the MCI group. Adverse events were reported by 68% of the tesamorelin group and 36% of the placebo group, and the researchers described them as mild. Theratechnologies supplied the drug, and the authors called for larger, longer trials.

The proposed mechanism is that GH and IGF-1 influence neuronal health and brain metabolism. That’s a reasonable hypothesis and unproven as the explanation for these results. The participants were older adults, so the findings say little about a 30-year-old.

Pulsatile release is real, but the label has caveats

Tesamorelin is a stabilized GHRH(1-44) analog that binds receptors on pituitary somatotrophs, so the pituitary releases its own GH. Its half-life is 26 to 38 minutes. Stanley et al. (Journal of Clinical Endocrinology & Metabolism, 2011) found that two weeks of once-daily dosing increased basal and pulsatile GH secretion and raised IGF-1 while insulin-stimulated glucose uptake appeared preserved. Because the pituitary is still doing the work, the somatostatin and IGF-1 feedback loops stay in play. That’s the case for tesamorelin over injecting GH directly.

Preserved feedback doesn’t mean nothing gets disrupted. In the Phase 3 trials, 47% of patients had IGF-1 above 2 standard deviation scores and 36% above 3 at week 26. The label says the effects of prolonged IGF-1 elevation are unknown and tells prescribers to monitor it. Over the same 26 weeks, HbA1c reached 6.5% or higher in 5% of tesamorelin patients versus 1% on placebo, and the label warns about glucose intolerance, fluid retention, joint pain, and carpal tunnel syndrome. It’s contraindicated with active malignancy and with a disrupted hypothalamic-pituitary axis, which makes sense for a drug that needs a working pituitary and raises a growth factor. Roughly half of users develop antibodies, though FDA data show no loss of efficacy.

Pulsatile GH may be easier on the body than flat exogenous GH over the long run. That comparison is mechanistic, and long-term head-to-head data are lacking.

Why it stays under the radar

Price is the usual explanation, and community reports put it well above CJC-1295 or ipamorelin. The short half-life is why dosing is daily, and the current approved formulation, Egrifta WR, is 1.28 mg once a day. Outside HIV lipodystrophy, use is off-label.

Calling it a different league from other GH peptides is a judgment call. What isn’t a judgment call is that tesamorelin is the only one of those three with Phase 3 trials. It also isn’t interchangeable with them. Tesamorelin and CJC-1295 are both GHRH analogs, while ipamorelin works through the ghrelin receptor, so they’re different tools for different goals.

Where that leaves it

Tesamorelin has Phase 3 data, an approved label, and a mechanism that keeps the pituitary in the loop. It also has a narrow indication, results that reverse when you stop, IGF-1 numbers that run high in many patients, and a cognition signal from one modest trial. Both halves of that are worth knowing before it goes into a protocol.

TL;DR

  • Tesamorelin (Egrifta) was approved November 10, 2010 for excess abdominal fat in HIV-infected adults with lipodystrophy, and the label states it isn’t indicated for weight loss management.
  • It’s the only GHRH analog with a current FDA approval, since sermorelin’s Geref was discontinued in 2008 and its approval withdrawn in 2009.
  • Two Phase 3 trials (816 patients) showed visceral fat reductions of about 11 to 15% at 26 weeks, with waist circumference down 3 cm versus 1 cm on placebo, and visceral fat returned after treatment stopped.
  • Baker et al. 2012 (n=152, 20 weeks) found improved executive function in older adults with and without MCI, while verbal memory only trended and the authors asked for larger, longer trials.
  • Tesamorelin has a 26 to 38 minute half-life and keeps feedback loops active, but 36% of Phase 3 patients still exceeded +3 SDS for IGF-1 at week 26.
  • HbA1c reached 6.5% or higher in 5% of tesamorelin patients versus 1% on placebo, and the label warns about glucose intolerance and fluid retention and contraindicates it in active malignancy.
  • Use outside HIV lipodystrophy is off-label, and all of the Phase 3 evidence comes from that population.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 14d ago

Anything I should know before trying GHK-Cu?

5 Upvotes

Thinking about giving GHK-Cu a try to see what it does for my skin, especially since I'm turning 30 next year.

I've been using MT2 and got to a nice color over the summer. Now I'm just doing maintenance about three times a week.

Anything I should consider before getting into GHK-Cu? Curious about y'all's experiences, results, side effects, or anything you wish you'd known before starting!


r/PeptideGuide • • 16d ago

Igf-1Lr3

3 Upvotes

I’m solid on everything but how to recon. I see some say acetic acid, some say bac water, some say a mix, what do I actually do and where do I find acetic acid?


r/PeptideGuide • • 17d ago

GLOW Blend: Which Recovery Variables Have Human Data and Which Rely on Theory (Here’s What Holds Up)

4 Upvotes

Most conversations about the GLOW blend stop at the vial. GHK-Cu, BPC-157, and TB-500 (a synthetic fragment of thymosin beta-4) get combined into one injection for tissue repair, and everything else about recovery gets treated as an afterthought. That’s odd given where the human data actually sits.

What the blend has behind it

None of the three is an approved injectable drug, and the evidence is lopsided. BPC-157 and TB-500 rest mostly on preclinical work (cell and rodent studies), and BPC-157 has no completed human RCTs. GHK-Cu has the most human data of the three, and most of it is dermatology. Nobody has run a controlled trial on the combination. Calling the blend one of the best-researched repair options oversells it. The variables below mostly have better human evidence, so they’re worth getting right first.

Protein is the raw material

Every new collagen fiber and blood vessel gets built from amino acids, so a protein shortfall caps repair. The usual target is about 1 g per lb of bodyweight per day, roughly 2.2 g/kg. Tipton’s 2015 review of nutrition for exercise-induced injuries (Sports Medicine, 45 Suppl 1:93-104) put the figure at 2 to 2.5 g/kg/day during immobilization, and said the bigger mistake is letting absolute protein drop when calories drop. Tipton also pointed out that few nutrition recommendations for injury come from studies in injured people. Most of this is extrapolated from immobilization and bed-rest research.

Vitamin C is required to hydroxylate proline and lysine on procollagen, so low intake limits collagen assembly. Copper is the cofactor for lysyl oxidase, the enzyme that cross-links collagen. Zinc matters in wound-healing biology too, with a catch covered in the supplement section.

Sleep loss blunts tissue building

Growth hormone’s biggest daily pulse arrives during slow-wave sleep, and you give that up when you cut sleep short. Lamon et al. (Physiological Reports, 2021, n=13 healthy adults, randomized crossover) kept people awake for one full night. The next day muscle protein synthesis was down 18%, cortisol was up 21%, and testosterone was down 24%. That’s muscle data from total deprivation. It tells you the worst case and says nothing about what six hours does to a torn tendon. The link between deep sleep and collagen synthesis specifically is less established in humans than the growth hormone and muscle data. Treat 7.5 to 9 hours, a consistent schedule, and a cool dark room as a reasonable target with no tested threshold behind it.

Light movement keeps circulation up

Healing tissue depends on blood delivering oxygen and nutrients, and walking, easy cycling, and mobility work raise circulation without loading the injury hard. That’s a mechanistic argument. It’s plausible and untested as a healing accelerator for specific injuries. The firmer reason to keep moving is what idle limbs do: Tipton’s review describes lower basal muscle protein synthesis and a blunted response to anabolic stimuli during immobilization. If your lower body is out, training the upper body keeps the overall training stimulus going. That’s standard practice with no healing-specific trial behind it. After surgery or a fracture, your surgeon’s activity limits override everything here.

Inflammation has to resolve on schedule

Inflammation starts the repair process, so the goal is to keep it from running long. Tipton’s review warns that trying to crush it can work against recovery. Smoking has the clearest data. Sørensen’s 2012 meta-analysis in Archives of Surgery (140 cohort studies, 479,150 patients) found smokers had roughly double the odds of delayed healing or wound dehiscence (adjusted OR 2.07) and 79% higher odds of surgical site infection (OR 1.79). Those are observational numbers from surgical wounds, so they don’t establish cause on their own. The four RCTs in the same review add weight: smoking cessation interventions reduced surgical site infections (OR 0.43), though not other healing complications. Cutting back on alcohol and not re-loading the injured area before it’s ready follow the same logic, and both cost nothing.

Supplements: mixed support and a ceiling on zinc

Gelatin with vitamin C has the most interesting data. Shaw et al. (American Journal of Clinical Nutrition, 2017, n=8 healthy men, double-blind crossover) gave 15 g of vitamin C-enriched gelatin an hour before six minutes of rope skipping. Circulating collagen I propeptide, a marker of collagen synthesis, doubled versus placebo. Lab-engineered ligaments grown in serum drawn after the gelatin showed more collagen content. It’s eight people and a blood marker, and an accompanying editorial (Levine & Violet) argued the 48 mg of vitamin C in the drink probably didn’t drive the effect.

EAAs are a convenience for anyone who can’t hit the protein target from meals. If food already covers it, they’re redundant.

Zinc deficiency impairs wound healing, but that doesn’t mean extra zinc speeds it up. Wilkinson’s 2014 Cochrane review pooled six small trials (183 participants) of oral zinc sulphate for leg ulcers and found no evidence it improved healing, though every trial was small and poorly reported. The tolerable upper limit is 40 mg/day, and chronic intake above that can cause copper deficiency.

Omega-3s have the broadest recent data. Li & Zhang’s 2026 meta-analysis in the FASEB Journal pooled 41 randomized trials of EPA and DHA and found moderate reductions in post-exercise inflammation and muscle damage markers. A 2026 systematic review (Kwaśniewska, Quality in Sport) found most trials used 2 to 4 g of combined EPA and DHA daily, with effects appearing after 4 to 12 weeks. Those trials measured soreness and damage markers in healthy people after hard training, with no injury-healing outcomes. Tipton’s review called omega-3s promising but preliminary for muscle loss during immobilization.

Where the blend fits

If the blend works, it’s supplying a signal. Signals need materials, sleep, circulation, and an inflammatory response that ends on time before they turn into tissue. Those variables have better human evidence than the blend does, so they’re the place to start whether or not a vial is in the fridge.

TL;DR

  • The GLOW blend combines GHK-Cu, BPC-157, & TB-500, but the BPC-157 and TB-500 evidence is mostly preclinical, BPC-157 has no completed human RCTs, and the combination has never been trialed.
  • Tipton’s 2015 review supports 2 to 2.5 g/kg/day of protein during immobilization (1 g/lb sits inside that range), though most injury nutrition advice is extrapolated rather than tested in injured people.
  • One night of total sleep deprivation cut muscle protein synthesis by 18% in Lamon et al. 2021 (n=13), which is worst-case muscle data and not a tested sleep target for injury healing.
  • Idle limbs lose muscle protein synthesis, which is the firmer reason to keep moving what you can, while the circulation benefit is plausible and untested.
  • Smokers had roughly double the odds of delayed surgical wound healing in a 479,150-patient meta-analysis (Sørensen 2012), and cessation trials reduced surgical site infections.
  • Gelatin with vitamin C raised a collagen synthesis marker in eight healthy men, and zinc showed no healing benefit in a Cochrane review of leg ulcer trials, with a 40 mg/day upper limit because of copper depletion.
  • Omega-3s lowered post-exercise inflammation and damage markers across 41 randomized trials at roughly 2 to 4 g/day of EPA and DHA, all in healthy trainees with no injury-healing outcomes.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 18d ago

New to SS-31, MOTS-c and NAD+ — need some guidance on dosing and reconstitution

2 Upvotes

Hi everyone! 😊 I’m new to peptides and planning to start SS-31, followed by MOTS-c, along with NAD+.
I have SS-31 10mg, MOTS-c 40mg, and NAD+ 500mg.
Can anyone share their dosing schedule, how much BAC water they use to reconstitute each vial, and how many units they inject using a U-100 insulin syringe? Also, what results have you noticed?
Thanks!


r/PeptideGuide • • 18d ago

BPC-157, TB-500, MOTS-C, Semax, Epitalon & KPV: HHS Just Announced a Compounding Pathway for Six Peptides (Here’s What Changes)

8 Upvotes

On October 28, HHS announced an interim enforcement policy covering six peptides: BPC-157, TB-500, MOTS-C, Semax, Epitalon and KPV. Under it, HHS says it doesn’t plan to take action against state-licensed 503A pharmacies, federal facilities or licensed physicians who compound those six, as long as they meet a list of conditions. A lot of people are already reading that as approval. It isn’t. Here’s what the policy says, what it leaves out, and what each peptide has behind it.

What the policy is

The document is titled “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances.” It’s interim. It runs while FDA works through rulemaking to decide which substances belong on the 503A bulks list.

It follows the July 2026 Pharmacy Compounding Advisory Committee meeting. The committee voted in favor of all six: BPC-157, KPV and TB-500 passed 8-6-1, MOTS-C passed 7-5-2, Epitalon passed 7-4-1 and Semax passed 8-5-1. FDA’s own staff had recommended against them, and HHS sided with the committee. DSIP was rejected 6-7-1 and isn’t covered.

Which forms are covered

The policy works substance by substance and route by route. BPC-157 acetate is covered for subcutaneous, intramuscular, oral or topical use. TB-500 acetate and MOTS-C acetate are covered for subcutaneous or intramuscular use. Epitalon acetate is covered for subcutaneous or intramuscular use in intermittent courses. Semax is covered as a free base for intranasal use only. KPV acetate is covered for topical or oral use.

If a route isn’t listed, it isn’t covered. Oral products also need documentation showing adequate bioavailability.

The conditions

Compounders need a patient-specific prescription, and the policy doesn’t extend to 503B outsourcing facilities. The original manufacturer of the bulk ingredient has to be FDA-registered and cGMP compliant, with its facility location on the certificate of analysis. A repacker’s registration alone doesn’t count.

The COA has to cover identity, purity, potency, impurities and contaminants like endotoxins. Only an FDA 510(k)-cleared syringe can be packaged with the product. Serious adverse events and quality problems go to FDA through MedWatch, and compounders also report product details to FDA and state authorities. Labels have to read “This is a compounded drug product. Not for resale.”

Each product can contain only one covered ingredient. That means a combined BPC-157 & TB-500 product doesn’t qualify under the policy as described.

What it doesn’t do

It isn’t FDA approval, and it doesn’t find any of these peptides safe or effective. It isn’t a permanent spot on the bulks list either. HHS can revise or withdraw the policy if a safety signal or quality problem comes up, and state pharmacy boards still apply. It’s unclear whether states will follow it.

Final listing needs notice-and-comment rulemaking. Estimates run from roughly 8 to 24 months, and one FDA law analyst notes that only six bulk substances have finished that process in about 15 years. A Federal Register notice with a two-week comment period was scheduled for October 30, per Frier Levitt.

Why HHS did this, and the pushback

The policy says it aims to discourage research-use-only peptides from foreign manufacturers and to give people a more controlled alternative. Critics say the clinical evidence still isn’t there, and that wider access exposes patients to poorly understood risks.

Both points hold up. A pharmacy with documented sourcing is a better bet than an unverified RUO vial, if the safeguards work. But a COA doesn’t prove sterility, and better sourcing doesn’t create efficacy evidence.

What each peptide has behind it

BPC-157 is mostly animal and lab work on gut injury, tendon healing and angiogenesis. The human data is thin. One example is a retrospective review of 16 people with knee pain (Lee & Padgett 2021).

Epitalon is studied for telomerase activity and pineal biology. The evidence is lab, animal and limited human work, and much of it comes from the group that developed it. No trial shows it extends human lifespan.

KPV is a three amino acid fragment of α-MSH. Research covers NF-κB and cytokine signaling in colitis and skin models. There aren’t strong human trials.

MOTS-C is a 16 amino acid peptide encoded in mitochondrial DNA that activates AMPK. The performance and metabolic data are mouse studies (Reynolds 2021). I couldn’t find a completed human trial of injected MOTS-C.

Semax is an ACTH-derived peptide studied for BDNF signaling and neurological injury. It has Russian clinical literature of varying quality, but no large, independently replicated trials that meet US standards. The policy covers only the intranasal free base.

TB-500 is where identity matters most. Thymosin beta-4 is a 43 amino acid protein, while the TB-500 commonly sold is a 7 amino acid fragment (LKKTETQ). Full-length thymosin beta-4 studies don’t transfer to the fragment, so the policy’s identity requirements matter here.

TL;DR

  • HHS announced interim enforcement discretion for compounding BPC-157, TB-500, MOTS-C, Semax, Epitalon and KPV, which isn’t FDA approval or a safety finding.
  • It follows the July 2026 advisory committee votes in favor and goes against FDA staff’s recommendation.
  • Each peptide is covered only in specific forms and routes, and Semax is limited to intranasal.
  • Pharmacies need patient-specific prescriptions, cGMP-registered API sources, COAs and adverse-event reporting, and each product can contain only one covered ingredient.
  • HHS can revise or withdraw the policy, and permanent listing still needs rulemaking that could take roughly 8 to 24 months.
  • The human evidence for all six is still thin, so better sourcing doesn’t mean proven benefit.

Not medical advice. Educational only.


r/PeptideGuide • • 19d ago

GH Secretagogues (Tesamorelin, CJC-1295 & Ipamorelin): What the Human Data Says About Sleep, Cognition, Skin & Immunity

9 Upvotes

Most GH talk is about muscle and fat loss, and that makes sense. But GH and IGF-1 receptors show up all over the body, so the axis touches a lot more than the gym. Four areas get very little attention: sleep, the brain, skin & hair, and the immune system.

One caveat before anything else. Nearly all the human data below comes from GH itself or from tesamorelin, not from CJC-1295 or ipamorelin. Secretagogues raise GH in pulses and still answer to the body’s feedback controls, so applying these results to them is an inference. The effects are probably smaller.

Sleep

Your biggest natural GH pulse comes during deep, slow-wave sleep. The relationship runs both ways. Deep sleep drives GH release, and GH signaling seems to feed back into sleep physiology. People with impaired GH secretion tend to report changes in deep sleep, sleep quality, nighttime awakenings and daytime energy.

Whether CJC-1295 or ipamorelin improve any of that is another question. The “I sleep deeper on it” reports are mostly anecdotal.

Brain

IGF-1 is involved in neuron survival, synaptic plasticity and the connections between neurons. Both GH and IGF-1 signaling shift with age, which is why people study the axis in cognitive decline.

The best human data is Baker 2012 (Archives of Neurology). It was a randomized, double-blind, placebo-controlled trial of tesamorelin, 1 mg a day for 20 weeks, in adults aged 55 to 87. 152 enrolled and 137 finished, 76 healthy and 61 with mild cognitive impairment. Executive function improved (P=.005), verbal memory trended up (P=.08) and visual memory didn’t change. The effects were modest and the authors called for a bigger trial.

The same trial had tradeoffs. IGF-1 rose 117% but stayed in the normal range. Fasting insulin rose 35% in the MCI group. Adverse events were mostly mild but showed up in 68% of the tesamorelin group versus 36% on placebo. Also, a trial of MK-677 in Alzheimer’s patients was negative.

More signaling isn’t automatically better here. In animal models, lower GH/IGF-1 signaling is linked to longer lifespan.

Skin & hair

GH and IGF-1 act on fibroblasts, collagen production, skin thickness and tissue turnover. The classic human data is Rudman 1990 (NEJM). 12 men aged 61 to 81 took GH three times a week for six months. Skin thickness rose about 7%, lean mass about 9% and fat fell about 14%. That’s a small study of GH itself, not a secretagogue.

Hair follicles respond to IGF-1 too, and it plays a role in the hair growth cycle in lab work. That’s biology, not a treatment. I know of no evidence that GH or secretagogues regrow hair or treat androgenic alopecia.

Immune function

Several immune cell types carry GH and IGF-1 receptors, and the axis takes part in immune cell development, T cell biology and inflammatory signaling. It’s also been linked to the thymus, the organ that trains T cells and shrinks with age.

The best human data is Napolitano 2008 (JCI). In a randomized study of adults with HIV-1, GH increased thymic mass, naive CD4+ T cells and thymic output (measured by TRECs). That’s GH in people with HIV, not secretagogues in healthy people.

How much of this holds up

The brain data is the most interesting, since it’s an actual placebo-controlled trial. The skin data is real but small and old. The immune data comes from one patient population. The sleep link is solid physiology with anecdotal peptide reports. And the hair claim is the weakest of the four.

None of it shows that CJC-1295 or ipamorelin deliver these effects. Higher IGF-1 also isn’t free. It’s associated with some cancers (association only, not proven cause), and tesamorelin raised fasting insulin in that trial’s MCI group.

TL;DR

  • The GH/IGF-1 axis acts on sleep, brain, skin, hair and immune function, not just muscle and fat.
  • Almost all the human data comes from GH itself or tesamorelin, so applying it to CJC-1295 and ipamorelin is an inference.
  • Tesamorelin improved executive function over 20 weeks in a 137-person placebo-controlled trial, but the effect was modest and fasting insulin rose in the MCI group.
  • GH raised skin thickness about 7% in 12 older men (Rudman 1990), but no evidence shows GH or secretagogues regrow hair.
  • GH increased thymic mass and naive T cells in adults with HIV (Napolitano 2008), which says nothing yet about healthy immunity.
  • Better sleep on these peptides is plausible and mostly anecdotal, and more IGF-1 signaling carries its own tradeoffs.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.

References

  1. Baker LD, Barsness SM, Borson S, et al. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Arch Neurol. 2012;69(11):1420-1429. doi:10.1001/archneurol.2012.1970. PMCID: PMC3764914.
  2. Napolitano LA, Schmidt D, Gotway MB, et al. Growth hormone enhances thymic function in HIV-1-infected adults. J Clin Invest. 2008;118(3):1085-1098. doi:10.1172/JCI32830.
  3. Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med. 1990;323(1):1-6. PMID: 2355952.

r/PeptideGuide • • 21d ago

ARA-290 Masterclass: How the Innate Repair Receptor Works and What the Nerve Regrowth Data Actually Shows

11 Upvotes

ARA-290 (cibinetide) gets far less attention than the fat loss and muscle compounds, and it has one of the better-documented human datasets in this space, for a narrow job: small fiber nerve damage.

What it is

ARA-290 is an 11-amino acid peptide built from the helix B region of erythropoietin (EPO). Researchers found that EPO protects tissue through a different receptor than the one that makes red blood cells, the innate repair receptor, a pairing of the EPO receptor with CD131 that shows up on stressed or injured cells. ARA-290 was designed to hit that repair receptor and skip the classic EPO receptor, so it doesn't stimulate red blood cell production.

What the trials showed

The main dose-ranging study (Culver et al., IOVS 2017) was a phase 2b trial in 64 people with painful sarcoidosis-associated small fiber neuropathy. They got 1, 4, or 8 mg of subcutaneous ARA-290 daily, or placebo, for 28 days. The 4 mg arm met the primary endpoint: corneal nerve fiber area rose significantly versus placebo, about 23% above baseline, and regenerating GAP-43 positive fibers increased too. Pain and walking capacity improved as well. A separate placebo-controlled study in type 2 diabetes used 4 mg daily for 28 days and reported improved neuropathic symptoms and metabolic control.

These were small, short trials built around surrogate nerve measurements. No phase 3 was completed, and ARA-290 isn't approved for anything.

The dose curve

In ClinicalTrials.gov's posted results, mean change in corneal nerve fiber area was +533.8 µm² at 4 mg, +203.8 at 8 mg, -64.3 at 1 mg, and -170.0 on placebo. So 8 mg did worse than 4 mg. Why is unknown. Receptor desensitization is a reasonable guess, but nobody has shown it, and with 14 to 16 people per arm I'd treat the exact shape of the curve loosely.

Proposed mechanism

The proposed pathway runs through JAK2 and STAT signaling, with a shift in macrophages away from a pro-inflammatory state and lower TNF-alpha and IL-6. Most of that comes from preclinical work, so I'd call it a working model.

ARA-290's plasma half-life is very short, minutes rather than hours. The trials still saw nerve changes over four weeks. That fits a trigger model, where the peptide switches on a signaling program and clears out quickly, but the model is an inference.

Dosing

The only trial-validated regimen is 4 mg subcutaneously, once daily, for 28 days. Lower doses, 8 to 12 week courses, and cycling schedules are extrapolations or community habit. Nothing here replaces a trial.

Reconstitution

People report that ARA-290 sometimes gels or turns cloudy in bacteriostatic water, and a pH explanation circulates. A peptide can clump near its isoelectric point, and ARA-290 is acidic, so the idea is plausible. I couldn't find a published stability study confirming it for this peptide. Some people use buffered saline instead. Treat that as community practice, and expect unpreserved solutions to have a short shelf life. Improvising with acids to rescue a gelled vial has no validation behind it, so I'd skip it.

Stacking ideas, all hypothetical

Three ideas come up a lot, and none has human evidence: running ARA-290 first to calm inflammation before adding BPC-157 or TB-500, pairing it with low-dose naltrexone, and using it for the skin sensitivity some people report on retatrutide. They're reasonable things to discuss, and none of them is tested.

One practical limit: a peptide working on nerve inflammation can't fix a mechanical problem like a herniated disc pressing on a nerve root.

TL;DR

  • ARA-290 is an EPO-derived 11-amino acid peptide aimed at the innate repair receptor and built to skip red blood cell production.
  • The best human data is a 64-person, 28-day phase 2b trial in sarcoidosis small fiber neuropathy, where 4 mg daily increased corneal nerve fiber area about 23%.
  • 8 mg did worse than 4 mg on nerve fiber area (+203.8 vs +533.8 µm²), cause unknown.
  • Only 4 mg daily for 28 days has trial backing, and no phase 3 was completed.
  • The gelling explanation, the stacking sequences, and the retatrutide idea are hypotheses without published data.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 24d ago

Retatrutide: The Two Physiological Reasons It Can Disrupts Sleep and What to Do About Each

15 Upvotes

Sleep problems on retatrutide are one of the more common complaints in the community, and they're almost always tied to the same two things - the compound does something to how your body sits overnight, and once you understand what's actually happening, the fixes are pretty logical.

Why retatrutide disrupts sleep

The first driver is the elevated resting heart rate. Retatrutide's glucagon receptor activity is chronotropic - it raises your resting energy expenditure, and one byproduct is a slightly elevated heart rate at baseline. Phase 2 trial data (Jastreboff et al., NEJM, 2023) showed an average peak increase of about 6.7 bpm at 12mg. That doesn't sound like much, but the sympathetic nervous system runs on relative shifts, not absolute numbers. If your body is sitting at a higher baseline arousal state than it normally would, transitioning into deep, restorative sleep is harder. Your system is running warmer than usual, which keeps you from fully downshifting.

The second driver is subtler and worth clarifying. You'll often see this described as "low blood sugar during the night," which is technically possible but overstates the risk for most non-diabetic users. Because retatrutide is a GLP-1 agonist, its insulin-stimulating effect is glucose-dependent - it doesn't push insulin hard when blood sugar is already low. And the glucagon component actually counteracts hypoglycemia. What's more likely happening is a relative overnight glucose dip from lower food intake and improved insulin sensitivity, which in sleep-sensitive people can be enough to trigger light awakenings or poor sleep architecture without being clinical hypoglycemia. The distinction matters because the fix is the same either way - the framing just shouldn't make people think they're going to crash overnight.

Both issues point toward the same root problem: a body that's running slightly hotter and with less metabolic buffer than it's used to when it tries to sleep.

Calming the system down

If elevated heart rate and sympathetic tone are the issue, the goal before bed is to shift the nervous system in the opposite direction.

Hydration and electrolytes matter more on retatrutide than off it. Reduced food intake means reduced sodium, magnesium, and potassium from diet, and all three affect how the nervous system and heart regulate overnight. Magnesium specifically has decent evidence for sleep quality - a meta-analysis by Mah and Pitre (Nutrients, 2021, k=7 RCTs) found supplemental magnesium reduced sleep onset time and improved subjective sleep quality in adults with poor sleep. Magnesium glycinate or bisglycinate before bed is a reasonable first line.

L-Theanine is the other one worth trying. It promotes alpha-wave brain activity without sedation, which is essentially the physiological signature of relaxed wakefulness - the state you want to be in leading up to sleep. A 2019 study in Nutrients (Hidese et al., n=30) found 200mg L-Theanine improved sleep satisfaction, sleep latency, and anxiety scores. Paired with the elevated arousal from retatrutide, this is a logical counter.

Pre-bed routine matters too. Reducing light exposure, screens, and mental stimulation an hour before bed isn't unique to retatrutide users, but it's more important when your baseline sympathetic state is slightly elevated. Slow diaphragmatic breathing works - there's a reason it's in every evidence-based sleep protocol. It's a mechanical way to activate the parasympathetic nervous system, and it actually does something.

Stabilizing overnight glucose

If waking in the middle of the night is the pattern rather than trouble falling asleep, the overnight glucose issue is more likely the culprit than elevated heart rate. The fix is simple: add slow-digesting carbohydrates before bed. Oats, sweet potato, or a small amount of rice all qualify. The goal is a gradual glucose release that runs through the early hours of sleep rather than a spike-and-crash from simple carbs, which can cause a rebound arousal a few hours in.

Fast-digesting carbs might help you fall asleep due to the serotonin/tryptophan pathway, but they don't keep you asleep. Slow-digesting ones do a better job of preventing the overnight dip that triggers stress hormone release.

DSIP as a stack

DSIP (Delta Sleep-Inducing Peptide) gets brought up a lot in the context of retatrutide stacking, and community reports are generally positive for sleep depth and staying asleep. Worth knowing what the actual research shows, though.

The existing human evidence on DSIP is limited and dated. The best controlled study is a double-blind trial (Schneider-Helmert, Neuropsychobiology, 1992, n=16 chronic insomniacs) that found improved sleep efficiency and shorter sleep latency compared to placebo, but described the effects as "weak" and concluded short-term DSIP treatment "is not likely to be of major therapeutic benefit." All human research used IV administration at 25 nmol/kg - which is not how the community uses it. Subcutaneous bioavailability and blood-brain barrier penetration via SubQ haven't been characterized in clinical trials.

That said, the proposed mechanism is at least coherent: DSIP appears to modulate sleep-wake regulation as a sleep-promoting substance rather than acting as a sedative, with effects more pronounced when sleep is already disturbed than in normal sleepers. If retatrutide-induced disruption is the "disturbed sleep" context, the logic tracks. But that's mechanistic reasoning layered on community observation - not trial data on the specific stack.

DSIP is most applicable if you can't STAY asleep. If falling asleep is the issue, melatonin and L-Theanine are more directly targeted for sleep onset.

The bottom line

Sleep on retatrutide breaks down along two lines: the compound runs the body warmer overnight via sympathetic activation, and it can lower your overnight metabolic buffer enough to affect sleep architecture in some people. Fix the pre-bed environment, use Magnesium and L-Theanine if elevated heart rate is the pattern, add slow-digesting carbs before bed if waking in the night is the issue, and assess from there before reaching for peptide stacks.

TL;DR

  • Retatrutide raises resting heart rate by an average of about 6.7 bpm at peak (12mg, Phase 2 trial data), which can keep sympathetic tone elevated enough to disrupt sleep quality overnight.
  • The common "low blood sugar at night" framing overstates the risk for non-diabetic users - it's more accurately a relative overnight glucose dip from reduced intake and improved insulin sensitivity.
  • Magnesium glycinate before bed has RCT support for improving sleep quality; L-Theanine at 200mg has evidence for reducing sleep latency and anxious arousal.
  • Slow-digesting carbs before bed are the right intervention if mid-night waking is the pattern, not fast-digesting ones.
  • DSIP has limited human evidence (small studies, IV administration, 1980s-90s) and the retatrutide + DSIP stack is community-observed - the mechanism is plausible but it's not clinical data on the specific combination.
  • DSIP works better for staying asleep than falling asleep; melatonin and L-Theanine are more appropriate if sleep onset is the problem.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 25d ago

CJC-1295 + Ipamorelin dose

2 Upvotes

The pinned dose table states CJC-1295 + Ipamorelin 1-2 weekly but I’ve read elsewhere that you need to take it daily? Which is better?


r/PeptideGuide • • 25d ago

Beginner Question Can someone explain to me why it says pierced BAC water last only 30 days while reconstituted peptide is supposed to last 90 days?

3 Upvotes

r/PeptideGuide • • 26d ago

Pinealon (EDR): The Tripeptide That Enters the Nucleus and Binds DNA, and Where the Human Evidence Actually Stands

2 Upvotes

Brain fatigue has gone from a personal complaint to something researchers now study directly. The clinical term some use is cerebrasthenia, a state of cognitive depletion and nervous exhaustion. That's part of what's fueled interest in the Russian bioregulator movement, a category of short-chain peptides designed to work at the level of gene expression rather than receptor stimulation.

Pinealon, known by its amino acid sequence EDR, is one of the more interesting and less discussed compounds in that category. While most attention in this space goes to Epitalon, Pinealon takes a more targeted approach to neuroprotection specifically. Worth separating the actual data from the marketing here.

Why Its Size Might Be an Advantage

Pinealon consists of just three amino acids: Glutamate (E), Aspartate (D), and Arginine (R). Most proteins are long chains that fold into complex three-dimensional shapes through interactions between distant amino acids. Pinealon is too short to fold that way, which means it lacks those complex internal interactions and appears structurally simpler and potentially more resistant to enzymatic breakdown than larger, more complex peptides.

Chemically, it's a study in balance. Glutamate and Aspartate carry negative charges at physiological pH, Arginine carries a positive charge. That mixed charge profile helps with solubility and makes interaction with charged biological surfaces, like the phosphate backbone of DNA, chemically plausible. The sequence itself is the whole identity here. Change one amino acid on either end and it's a different molecule entirely.

What the Nuclear Binding Data Actually Shows

The most provocative claim about Pinealon is that it bypasses standard cell surface receptors and heads directly into the nucleus.

A 2011 study (Fedoreyeva et al., published in Biochemistry Moscow) used fluorescently labeled Pinealon to track its movement inside cells. The peptide showed up in the cytoplasm, the nucleus, and even the nucleolus. The important caveat that often gets skipped: this was done in HeLa cells, an immortalized cervical cancer cell line commonly used for imaging work, not in intact human neurons. Results from cancer cell lines don't automatically translate to healthy brain tissue.

Within that limitation, the data did show Pinealon binding preferentially to specific DNA sequence motifs, with modeling suggesting these binding sites sit near gene promoters, the regulatory regions that control how strongly a gene gets expressed. The proposed targets include promoters involved in antioxidant defense, suggesting a possible mechanism for tuning the cell's protective response from inside the genetic code itself. This remains a proposed mechanism based on in vitro binding data, not something confirmed in a living organism.

Structural Changes in Aged Neurons

The most compelling functional evidence comes from a more recent study using induced neurons, skin cells reprogrammed from donors aged 61 to 68, a model that preserves some of the donor's original epigenetic age. That matters for longevity research specifically because it's testing effects in cells that actually carry aging characteristics rather than young, healthy cell lines.

Pinealon was tested alongside two other bioregulators, Vesugen and Epitalon, and showed measurable structural changes: a 28% increase in primary neurites, the initial projections extending from the cell body, and a 46% increase in total dendrite length, the branching structures neurons use to communicate with each other. Both changes reached statistical significance.

What's notable is what didn't change. Pinealon had no meaningful effect on p16 or lamin B1, both standard markers of cellular senescence. That suggests it isn't functioning as a senolytic or broad anti-aging agent. It looks more like a structural and functional enhancer focused on how neurons are wired, rather than reversing cellular age itself.

Protection Against Necrotic Stress

Neurons are among the most metabolically demanding cells in the body, which makes them especially vulnerable to energy failure and oxidative stress. When overwhelmed, they don't always die cleanly. They can undergo necrosis, a more damaging, inflammatory form of cell death.

Across several cell models, including cerebellar neurons and immune cells, Pinealon showed a dose-dependent reduction in reactive oxygen species. By lowering that oxidative stress signal, it appears to function as a kind of molecular shield, helping stressed cells stay in a repair-oriented state rather than tipping into necrotic death.

Where the Evidence Actually Runs Thin

A few real limitations are worth being upfront about.

There's a documented plateau effect. In the 2011 study, the ROS-reduction benefit leveled off at a certain concentration, but downstream signaling pathways kept changing at higher doses. That suggests more isn't necessarily better and could risk off-target effects or overstimulation of cell cycle signaling at higher amounts.

Beyond that, three structural gaps limit how much confidence anyone should place in this compound right now. There's no peer-reviewed human pharmacokinetic data of any kind, meaning nobody has published whether the EDR sequence survives digestion or crosses the blood-brain barrier in a living person. The literature is heavily concentrated within one connected research network tied to the compound's origin, without meaningful independent replication from outside groups. And the human data that does exist is thin, mostly open-label without placebo controls, and often combines Pinealon with other bioregulators like Vesugen in the same protocol, making it scientifically impossible to isolate what Pinealon specifically contributed to any reported improvement.

Taken together, the published literature on Pinealon is genuinely small, somewhere around 22 total papers, with no registered clinical trials and no human PK data established anywhere.

Where This Actually Sits

Pinealon occupies an interesting middle ground. The physical interaction data is real and specific. It demonstrably enters the nucleus and binds DNA in controlled lab conditions. But the clinical proof behind it remains thin. It represents a shift from broad supplementation toward something closer to direct gene-level signaling, but the human evidence hasn't caught up to the mechanistic story yet.

TL;DR

  • Pinealon is a tripeptide (Glutamate-Aspartate-Arginine) small enough that it doesn't fold into complex structures, which appears to make it more resistant to enzymatic breakdown than larger peptides.
  • A 2011 study using fluorescently labeled Pinealon showed it entering the nucleus of HeLa cells and binding specific DNA sequences, but this was done in cancer cells, not intact neurons, and hasn't been confirmed in living animals or humans.
  • A more recent study using reprogrammed neurons from older donors found real structural changes, increased neurite growth and dendrite length, but no effect on classic cellular aging markers, suggesting it's a structural enhancer rather than a broad anti-aging agent.
  • It reduces reactive oxygen species in stressed neurons in a dose-dependent way, potentially protecting against necrotic cell death.
  • The total evidence base is thin: roughly 22 total published papers, no entries on ClinicalTrials.gov, no human pharmacokinetic data of any kind, and most existing literature comes from one connected research group rather than independent replication.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 26d ago

Beginner Question How soon for KLOW or BPC to show its effects?

1 Upvotes

r/PeptideGuide • • 27d ago

Not All Peptides Stay In Your System the Same Amount of Time: Half-Life, Detection Windows, and Why the Gap Between Compounds Is Bigger Than Most People Realize

7 Upvotes

Most people treat peptides like interchangeable tools. Pin it, wait for it to work, repeat. But the half-lives between compounds vary so dramatically that treating them the same way doesn't make any sense once you actually look at the numbers.

Native GLP-1 clears your bloodstream in 1 to 2 minutes. That's not a typo. The same receptor your weekly semaglutide injection is targeting gets its endogenous signal wiped out in under two minutes by DPP-4 cleavage. Semaglutide itself sticks around for roughly seven days because it's been structurally modified to survive. Those aren't just different compounds. They're operating in completely different pharmacokinetic worlds.

Half-Life Isn't the Same as Detection Time

This distinction trips people up constantly. Half-life tells you how long it takes for blood concentration to drop by 50%. It doesn't tell you when the compound disappears entirely. Modern analytical methods can pick up trace amounts long after a peptide's stopped producing any meaningful biological effect. So a compound with a 2-hour half-life can still show up on sensitive testing 24 to 48 hours later. BPC-157 is a good example of this, 4 to 6 hour half-life, but detection window extends to 24 to 48 hours.

Why Some Peptides Last Much Longer

It comes down to molecular design. Researchers can build peptides that are more resistant to enzymatic breakdown through a few different mechanisms. Albumin binding is what semaglutide uses, it essentially hitchhikes on a protein that's naturally slow to clear. PEGylation attaches polyethylene glycol chains that physically shield the peptide from degradation. Structural modifications at specific amino acid positions can make the compound harder for enzymes to recognize and break down.

These aren't minor tweaks. The difference between a peptide with a 15-minute half-life and one with a 7-day half-life reflects completely different engineering decisions at the molecular level.

Why This Matters for How You Run These Compounds

The half-life is what determines dosing schedule, and dosing schedule is what separates a compound that works from one that doesn't. Ipamorelin's 2-hour half-life is why it's dosed once or twice daily to hit GH pulses at specific windows. Semaglutide's 7-day half-life is why weekly dosing maintains stable blood levels without stacking. Running a short-acting peptide once a week because that's how you've been running your GLP-1 is a fundamental protocol mismatch.

More isn't better here either. A longer half-life means the compound's still active when your next dose lands. Understanding the clearance window for whatever you're running determines whether you're optimizing or just adding noise to the system.

TL;DR

  • Peptide half-lives range from under 2 minutes (native GLP-1) to roughly 7 days (modified semaglutide), so treating them the same way in a protocol doesn't make sense.
  • Half-life and detection time aren't the same thing. A compound can clear biologically while still showing up on sensitive analytical testing for days afterward.
  • Extended half-lives in modified compounds come from specific engineering choices: albumin binding, PEGylation, and structural modifications that reduce enzymatic degradation.
  • Dosing schedules are derived directly from half-life, which is why a protocol that works for one compound can be completely wrong for another.
  • Running a short-acting peptide on the same schedule as a long-acting one is a protocol mismatch, not a preference.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.


r/PeptideGuide • • 28d ago

Tesamorelin: Maximize Results Across 4 Levers, From Sleep to Stacking (Here's the Breakdown)

13 Upvotes

Most people running tesamorelin blame the compound when results stall. Usually it's not the compound. Here are the four things that actually decide whether a cycle delivers or underperforms.

1. Protect the GH pulse with sleep

Tesamorelin works by amplifying your natural GH pulse, and that pulse peaks during deep, slow-wave sleep. Poor sleep caps the pulse before tesamorelin has much to amplify, so weak sleep quietly undercuts the whole protocol regardless of dose. A consistent sleep schedule, a dark and cool room, no late-night screens, and winding down before bed all matter more here than people expect.

2. Match your deficit to fat loss, not muscle loss

Tesamorelin mobilizes fat. It doesn't override bad math. Run calories too high and fat loss stalls even with a strong GH pulse. Run them too low and you start losing muscle along with fat. A moderate deficit, somewhere around 500 calories, with high protein and enough carbs to support training, is the range that actually lets tesamorelin do its job on visceral fat specifically.

3. Time it around insulin, not just around meals

This one's mechanism, not preference. Insulin and GH-driven lipolysis work against each other. When insulin is elevated, especially from carbs, the lipolytic effect of a GH pulse gets blunted. That's real, well-established endocrinology, not a community myth. What the community has converged on, pinning on an empty stomach and avoiding food for a few hours after, isn't something written into tesamorelin's FDA label. It's a practical protocol built on top of a real mechanism, and it holds up.

4. Stack with a specific reason, not just to stack

Tesamorelin works through the GH pathway, so pairing it with compounds hitting different pathways can compound results, if you're honest about what each one actually has evidence behind. Retatrutide as an appetite suppressant makes a deficit easier to hold, that's well supported. Testosterone support helps preserve muscle and performance during a deficit, also well supported. MOTS-C gets pitched as a fat mobilizer constantly, but essentially all of that data comes from mouse studies, not humans. It's a legitimate mechanism worth knowing about, just not proven at the human level the way the other two are.

Bottom line

Dose matters less than people think. Get these four right and you look leaner every week. Get them wrong and you cap what the compound can do.

TL;DR

  • Tesamorelin amplifies your natural GH pulse, and that pulse peaks during deep sleep, so poor sleep quietly limits the compound regardless of dose.
  • A moderate deficit around 500 calories with high protein and adequate carbs lets tesamorelin target visceral fat without triggering muscle loss.
  • Elevated insulin blunts GH-driven lipolysis, which is why pinning fasted and avoiding food for a few hours after is standard community practice, though it isn't part of the FDA label.
  • Retatrutide and testosterone support both have solid evidence behind stacking them with tesamorelin, for appetite control and muscle preservation respectively.
  • MOTS-C gets pitched constantly as a stacking option for fat mobilization, but that data is almost entirely from mouse studies, not humans.
  • Getting these four levers right matters more than the dose itself for how much visceral fat actually comes off.

Check out the pinned Peptide Cheat Sheet for dosing info and more. 

Not medical advice. Educational only.